A new round against aspiration thrombectomy

Original Title:  Aspiration thrombectomy prior to percutaneous coronary intervention in ST elevation myocardial infarction: a systematic review and meta-analysis.

Reference: Regina El Dib et al. BMC Cardiovascular Disorders (2016) 16:121.

Courtesy of Dr. Brian Nazareth Donato. 

thrombectomyBased on contradicting results obtained from different studies on the role of mechanical aspiration thrombectomy before PCI vs. PCI alone, this new meta-analysis seeks to determine the efficacy of routine use of this technique prior PCI.

MeSH, MEDLINE, EMBASE, and CENTRAL were searched for relevant studies comparing aspiration thrombectomy during PCI vs. PCI alone.

20 studies were included (ADMIT, Belum, Chao, De Luca, Expira, Export, Impact, INFUSE-AMI, ITTI, kaltoft, Liistro, REMEDIA, Shehata, Sim, TAPAS, TASTE, TOTAL, TROFI, VAMPIRE, Yim) with a total 20,866 patients and follow up periods varied between 30 and 365 days.

These studies randomized patients with ST elevation myocardial infarction to PCI + aspiration thrombectomy vs. PCI alone.

Global mortality rate:

  • PCI alone: 4.4%
  • Aspiration thrombectomy + PCI: 3.9%

(RR 0.89)

Recurrent MI rate:

  • PCI alone: 2.4%
  • Aspiration thrombectomy + PCI: 2.2%

(RR 094)

Stroke:

  • PCI alone: 0.5%
  • Aspiration thrombectomy + PCI: 0.8%

(RR 1.56)

Major bleeding:

  • PCI alone: 1.7%
  • Aspiration thrombectomy + PCI: 1.7%

(RR 1.02)

 

Conclusion

Evidence suggests the use of aspiration thrombectomy during primary PCI is associated to a small decrease in mortality (4/1000 patients) closely balanced by a small increase in stroke incidence (3/1000 patients). Therefore, because results are exiguous, aspiration thrombectomy should not be used as a routine strategy.

 

Editorial Comment

In 2015 AHA/ACC guidelines, evidence for the use of aspiration thrombectomy in the context of primary PCI is classified as IIb/C when there are intraluminal thrombi and class III when used as routine strategy for all cases.

The present meta-analyzis included randomized studies with different simple sizes, from 56 to more than 10 thousand patients, and therefore showed no net benefit in support of the systematic use of aspiration thrombectomy during primary PCI. Absolute effects are too small, 4 less deaths over 1000 patients and 3 more strokes over 1000 patients vs. PCI alone.

One of the most important limitations to these studies is the lack of a blind control group due to the nature of this intervention.

Even though today the available literature does not support routine aspiration thrombectomy to manage ST elevation myocardial infarction, there may be individual cases in which an operator may feel the potential benefit of this procedure outweighs its potential risks.

 

Courtesy of Dr. Brian Nazareth Donato. Hospital Britanico de Buenos Aires, Argentina.

 

Your opinion matters to us. You are most welcome to leave your comment, reflection, question or any ideas down below.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...